Our research program ranks second nationally among all urology departments for National Institutes of Health funding, with amounts totaling more than $6.7 million. Our multi-dimensional, interactive and highly transformative approach to research provides the foundation for the department's strong research standing.
Conducting research to help advance men’s health in the fields of male reproductive medicine, sexual medicine and surgery.
Analyzing the management and outcomes of patients born with congenital anomalies of the genitourinary system.
Evaluating robotic surgery techniques to improve patient outcomes and developing interventions to reduce kidney stone formation and recurrence.
Understanding racial health disparities in prostate cancer aggressiveness and outcomes.
Studying care delivery and quality of care for urologic patients.
Developing new agents and interventions to improve outcomes and quality of life for patients with chronic pelvic pain and benign urologic conditions.
Creating the next generation of diagnostic and therapeutic nanoparticles.
Performing basic science and clinical research to improve the treatment and outcomes for children with urologic conditions.
Studying molecular, genetic and environmental contributors to prostate cancer to improve prostate cancer prevention, diagnosis and treatment.
Establishing new urologic tissue reconstruction models and developing treatment strategies for inflammation-based urologic conditions.
Researching mechanisms of bladder and kidney cancer initiation and progression to develop novel therapeutics and treatments for genitourinary malignancies.
Clinical trials test or study drugs, surgical procedures, medical devices or interventions with human subjects. Read more about our actively recruiting clinical trials.
Our department wants to support our investigators in their efforts by making sure they’re updated on all of our policies for conducting responsible research and the many resources available to them.
Dr. Cooley is studying the immunological and genetic based differences in early and late bladder cancer tumorigenesis between genders. A mechanistic understanding of the gender differences in bladder cancer could translate to more precise therapeutic treatments of women to improve the gender disparity in bladder cancer and the survival of women with bladder cancer.
Dr. Hudnall is working with Dr. Joshua Halpern to determine the prevalence of testosterone deficiency in patients undergoing oncologic and non-oncologic surgery and to evaluate the surgical outcomes of patients with low serum testosterone.
Dr. Lai will conduct cost-effectiveness research to evaluate transrectal and transperineal prostate biopsy. This research will compare the potential cost and complication benefits of each approach to better understand how they compare in terms of their cancer detection, complications, and costs in order to deliver the most cost-effective care for our patients without compromising clinical outcomes.
Dr. Pham is evaluating surgeon-specific variation in transurethral resection of bladder tumors (TURBT) skill and its association with outcomes. He will utilize these findings to identify potential targeted interventions to improve surgeon skill and subsequent outcomes of TURBT.